サマリー

デビック症候群は、視神経脊髄炎としても知られており、特に眼神経と脊髄を侵す中枢神経系の疾患です。

市場分析と洞察。世界のデビック症候群（視神経脊髄炎）治療市場
Devic's Syndrome (Neuromyelitis Optica) Treatmentの世界市場規模は、2020年のXX百万米ドルから2027年にはXX百万米ドルに達すると予測され、2021年から2027年の間にXX％のCAGRで推移します。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界のDevic's Syndrome (Neuromyelitis Optica) Treatment市場で利用可能な主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つ見事な試みを行っています。本レポートの購入者は、Devic's Syndrome (Neuromyelitis Optica) Treatmentの世界市場全体の規模（売上高）など、検証済みの信頼できる市場予測にアクセスすることができます。
本レポートは、世界のDevic's Syndrome(Neuromyelitis Optica)治療市場において、競合他社に対して優位に立ち、永続的な成功を収めるための有効なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、Devic's Syndrome (Neuromyelitis Optica) 治療薬の世界市場を詳細に調査するために、独自の、そして業界で最も優れた調査・分析手法を用いています。

世界のDevic's Syndrome (Neuromyelitis Optica) Treatment（デビック症候群（視神経脊髄炎）治療）の範囲と市場規模
Devic's Syndrome (Neuromyelitis Optica) Treatment市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界のDevic's Syndrome (Neuromyelitis Optica) Treatment市場のプレーヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までの期間におけるタイプ別、アプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
エクリズマブ
メチルプレドニゾロン
Azathioprine
ミコフェノール酸モフェチル（Mycophenolate Mofetil
リツキシマブ

用途別セグメント
病院
クリニック
その他

地域別
北アメリカ
アメリカ
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
アレクシオン・ファーマシューティカルズ・インク
テバ・ファーマシューティカルズ
フレゼニウス・カビ社
ファルマシア・アップジョン(ファイザーの子会社)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
サンドス社(ノバルティス)
アルケム・ラボラトリーズ・リミテッド（Alkem Laboratories Ltd.
マイラン・ファーマシューティカルズ社（Mylan Pharmaceuticals, Inc.
ホフマン・ラ・ロシュ／中外製薬
MedImmune LLC（メディミューン
リメジェン社

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2016-2027)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Dynamic
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2016-2021)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2020
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2022-2027)

5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
6.2.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
6.2.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
6.2.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
6.3.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
6.3.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
6.4.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
6.4.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
7.2.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
7.4.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
8.2.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
8.3.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
8.4.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
9.2.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
9.3.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
9.4.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
10.2.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
10.3.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
10.4.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Details
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Details
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.3.5 Fresenius Kabi AG Recent Development
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Details
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.5.5 Lupin Ltd. Recent Development
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Details
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Development
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Details
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Development
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Details
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.8.5 Sandoz Inc. (Novartis) Recent Development
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Details
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.9.5 Alkem Laboratories Ltd. Recent Development
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Details
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Development
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Details
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.12.5 MedImmune LLC Recent Development
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Details
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.13.5 RemeGen, Ltd. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details